27
Participants
Start Date
February 17, 2010
Primary Completion Date
February 17, 2016
Study Completion Date
February 17, 2017
RAD001, Docetaxel, Bevacizumab
"RAD001 oral, 2.5 mg daily RAD001 oral, 5mg daily~Bevacizumab infusion (IV), 15 mg/kg every 21 days~Docetaxel infusion (IV), 75 mg/m\^2 every 21 days"
USC/Norris Comprehensive Cancer Center, Los Angeles
Westside Prostate Cancer Center, University of Southern California, Beverly Hills
Collaborators (2)
Novartis
INDUSTRY
Genentech, Inc.
INDUSTRY
University of Southern California
OTHER